Collaboration Deals With Pharma May Be Preferable To Licensing For Biotech
Executive Summary
Biotechs may want to look at deal structures with pharmaceutical companies outside of the traditional licensing model in order to have greater control over the development process, Medarex Senior Director of Development Melinda Shockley said at the recent Drug Information Association annual meeting in Philadelphia
You may also be interested in...
Venture Capital Still Has Place In Biotech Financing
SAN FRANCISCO-Despite biotech's increasing leverage in partnerships with big pharma, venture capital financing may still be the best way for biotech companies to maintain development control of early-stage products, several members of an industry panel said at the recent BIO Investor Forum
Venture Capital Still Has Place In Biotech Financing
SAN FRANCISCO-Despite biotech's increasing leverage in partnerships with big pharma, venture capital financing may still be the best way for biotech companies to maintain development control of early-stage products, several members of an industry panel said at the recent BIO Investor Forum
Big Pharma Seeking Simple Deals In Complex Biotech Licensing Environment
Large pharmaceutical manufacturers generally prefer biotech licensing deals that have simple structures, Bristol-Myers Squibb VP-Business Development Graham Brazier said